Alexander Guimaraes MD PHD LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$585	1
2021	Research	$2,295	1
2020	Research	$11,475	1
2019	Research	$31,340	11

Breakdown

Who paid Research payments · program years 2019–2022

Novartis Pharmaceuticals Corporation $26,820 4 payments
AstraZeneca Pharmaceuticals LP $16,855 1 payment
AbbVie, Inc. $2,020 9 payments

Studies the money was for Research payments · program years 2019–2022

A Randomized Double Blind Placebo Controlled Phase II Study of Everolimus in Combination With Exemestane in the Treatment of Chinese Postmenopausal Women With Estrogen Receptor Positive Her-2 Negative Locally Advanced Recurrent Or Metastatic Breast Cancer $24,525 3 payments
Phase 1b Open-label study to Evaluate the safety and tolerability of MEDI4736 in Combination with Tremelimumab in subjects with Advanced Non-small Cell lung Cancer $16,855 1 payment
A Randomized Double Blind Placebo Controlled Phase II Study of Everolimus in Combination With Exemestane in the Treatment of Chinese Postmenopausal Women With Estrogen Receptor Positive Her-2 Negative Locally Advanced Recurrent Or Metastatic Breast Cancer After Recurrence Or Progression on Prior Letrozole Or Anastrozole $2,295 1 payment
M14-064 $2,020 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.